title: [When and how prescribe antipsychotics?]
abstract: Antipsychotics are commonly prescribed in the general population since they have many indications. They can be used in acute care such as agitation or behavior disorders, or to treat more characterized psychiatric disorders like psychotic or mood disorders. Consequently, any practitioner will have to prescribe or renew a prescription of antipsychotics. These treatments require a benefit/risk balance assessment taking into account the specific context of each patient. Indeed, antipsychotics have many side effects, mainly neurological (extrapyramidal syndrome, dyskinesia, akathisia), metabolic and cardiac. If these complications are poorly controlled, they could dramatically increase the morbidity and the mortality. Second-generation antipsychotics should be preferred to first-generation antipsychotics because of their better safety profile, especially in case of prolonged prescribing. Treatment monitoring, including effectiveness on the targeted symptoms, tolerance and observance, are major issues in the management of patients treated with antipsychotics.
authors.affiliation: Faculté de médecine, université Paris 7 Denis Diderot, 75018 Paris, France; Service de psychiatrie, hôpital Louis-Mourier, AP-HP, 92700 Colombes, France.
authors.forename: S
authors.initials: S
authors.lastname: Tebeka
authors.affiliation: Faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Pôle psychiatrie et addictions, hôpitaux universitaires Paris Ouest, AP-HP, 75015 Paris, France; Inserm, Population-based Epidemiologic Cohorts Unit, UMS 011, 94800 Villejuif, France.
authors.forename: G
authors.initials: G
authors.lastname: Airagnes
authors.affiliation: Faculté de médecine, université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Pôle psychiatrie et addictions, hôpitaux universitaires Paris Ouest, AP-HP, 75015 Paris, France; Inserm, U894, centre de psychiatrie et neurosciences, 75014 Paris, France. Electronic address: frederic.limosin@aphp.fr.
authors.forename: F
authors.initials: F
authors.lastname: Limosin
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D016903:Drug Monitoring / Q000379:methods / Q000592:standards; D005602:France / Q000453:epidemiology; D006801:Humans; D008134:Long-Term Care / Q000592:standards; D010818:Practice Patterns, Physicians' / Q000592:standards* / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D014150:Antipsychotic Agents
keywords: Antipsychotic; Antipsychotique; Effets indésirables; Indication; Monitoring; Neuroleptic; Neuroleptique; Prescription; Side effects; Surveillance